HK1106495A1 - Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor - Google Patents
Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptorInfo
- Publication number
- HK1106495A1 HK1106495A1 HK07111922.3A HK07111922A HK1106495A1 HK 1106495 A1 HK1106495 A1 HK 1106495A1 HK 07111922 A HK07111922 A HK 07111922A HK 1106495 A1 HK1106495 A1 HK 1106495A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- dopamine
- receptor
- aminoethylaromatic
- respond
- modulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61888004P | 2004-10-14 | 2004-10-14 | |
| PCT/EP2005/011092 WO2006040179A1 (en) | 2004-10-14 | 2005-10-14 | Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1106495A1 true HK1106495A1 (en) | 2008-03-14 |
Family
ID=35478858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK07111922.3A HK1106495A1 (en) | 2004-10-14 | 2007-11-02 | Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8232426B2 (xx) |
| EP (2) | EP2371814A1 (xx) |
| JP (2) | JP4833989B2 (xx) |
| AT (1) | ATE540922T1 (xx) |
| CA (1) | CA2583918C (xx) |
| ES (1) | ES2380565T3 (xx) |
| HK (1) | HK1106495A1 (xx) |
| MX (1) | MX2007004357A (xx) |
| WO (1) | WO2006040179A1 (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040204422A1 (en) * | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
| EP2371814A1 (en) * | 2004-10-14 | 2011-10-05 | Abbott GmbH & Co. KG | Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| US8383641B2 (en) | 2006-04-14 | 2013-02-26 | Abbott Gmbh & Co. Kg | Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| BR112019012885B1 (pt) * | 2016-12-21 | 2022-12-27 | Bayer Cropscience Aktiengesellschaft | Processo para preparar derivados de 2-etilaminopiridina substituída |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2703688B1 (fr) | 1993-04-09 | 1995-05-19 | Rhone Poulenc Chimie | Réactif de désallylation, procédé de désallylation utilisant ledit réactif. |
| DK0923542T3 (da) * | 1996-05-31 | 2003-11-17 | Upjohn Co | Arylsubstituerede cycliske aminer som selektive dopamin-D3-ligander |
| TW450954B (en) | 1998-05-14 | 2001-08-21 | Pharmacia & Amp Upjohn Company | Phenylsulfonamide-phenylethylamines useful as dopamine receptors |
| DE19922443A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen |
| CA2428844A1 (en) * | 2000-11-14 | 2002-05-23 | Michael Stewart Hadley | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| US20020103198A1 (en) * | 2000-12-04 | 2002-08-01 | Fliri Anton F.J | Acylamino cyclopropane derivatives |
| WO2002066469A2 (en) * | 2001-02-16 | 2002-08-29 | Aventis Pharmaceuticals Inc. | Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands |
| GB0210762D0 (en) * | 2002-05-10 | 2002-06-19 | Glaxo Group Ltd | Compounds |
| EP2371814A1 (en) * | 2004-10-14 | 2011-10-05 | Abbott GmbH & Co. KG | Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
-
2005
- 2005-10-14 EP EP11158071A patent/EP2371814A1/en not_active Withdrawn
- 2005-10-14 EP EP05795920A patent/EP1809597B1/en active Active
- 2005-10-14 JP JP2007536106A patent/JP4833989B2/ja not_active Expired - Fee Related
- 2005-10-14 WO PCT/EP2005/011092 patent/WO2006040179A1/en active Application Filing
- 2005-10-14 CA CA2583918A patent/CA2583918C/en not_active Expired - Fee Related
- 2005-10-14 US US11/665,288 patent/US8232426B2/en not_active Expired - Fee Related
- 2005-10-14 AT AT05795920T patent/ATE540922T1/de active
- 2005-10-14 ES ES05795920T patent/ES2380565T3/es active Active
- 2005-10-14 MX MX2007004357A patent/MX2007004357A/es active IP Right Grant
-
2007
- 2007-11-02 HK HK07111922.3A patent/HK1106495A1/xx not_active IP Right Cessation
-
2011
- 2011-08-01 JP JP2011168735A patent/JP2012006946A/ja active Pending
-
2012
- 2012-02-27 US US13/405,646 patent/US20120220635A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20080096934A1 (en) | 2008-04-24 |
| US20120220635A1 (en) | 2012-08-30 |
| EP1809597A1 (en) | 2007-07-25 |
| JP4833989B2 (ja) | 2011-12-07 |
| ES2380565T3 (es) | 2012-05-16 |
| CA2583918A1 (en) | 2006-04-20 |
| EP1809597B1 (en) | 2012-01-11 |
| MX2007004357A (es) | 2007-07-17 |
| WO2006040179A1 (en) | 2006-04-20 |
| EP2371814A1 (en) | 2011-10-05 |
| JP2012006946A (ja) | 2012-01-12 |
| ATE540922T1 (de) | 2012-01-15 |
| US8232426B2 (en) | 2012-07-31 |
| JP2008516915A (ja) | 2008-05-22 |
| CA2583918C (en) | 2013-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200635582A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| HK1163545A1 (en) | Phenylpropionamide compounds and the use thereof | |
| ATE376828T1 (de) | Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms | |
| WO2007024717A3 (en) | Agents for preventing and treating disorders involving modulation of the ryr receptors | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| ATE534391T1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen | |
| TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| HK1166465A1 (en) | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as parp inhibitors for use in treating cancer | |
| WO2005086661A3 (en) | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | |
| MY139704A (en) | Naphthalene derivatives for use as histamine-3-receptor ligands | |
| TW200736233A (en) | Cyclohexyl piperazinyl methanone derivatives | |
| MX2007006387A (es) | Derivados de piridina 3-substituidos como antagonistas h3. | |
| IL200410A0 (en) | Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer | |
| EA200701181A1 (ru) | Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний | |
| TW200635595A (en) | Medicaments for the treatment of prevention of fibrotic diseases | |
| TW200637817A (en) | 5-aminoindole derivatives | |
| TW200735868A (en) | Compositions and methods for treating CNS disorders | |
| TW200728300A (en) | Therapeutic agents | |
| WO2007131907A3 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
| HK1106494A1 (en) | Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor | |
| HK1106495A1 (en) | Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor | |
| ATE445401T1 (de) | Verwendung von opioid-rezeptorantagonisten zur prävention und/oder behandlung von erkrankungen im zusammenhang mit dem target calcineurin | |
| IL206397A (en) | Cytotoxic substances, preparations containing these substances and their use in the treatment of tumors | |
| MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. | |
| HK1149263A1 (en) | Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20151014 |